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Available online 23 December 2013Abstract The ability to extract somatic cells from a patient and reprogram them to pluripotency opens up new possibilities for
personalized medicine. Induced pluripotent stem cells (iPSCs) have been employed to generate beating cardiomyocytes from a
patient's skin or blood cells. Here, iPSC methods were used to generate cardiomyocytes starting from the urine of a patient with
Duchenne muscular dystrophy (DMD). Urine was chosen as a starting material because it contains adult stem cells called
urine-derived stem cells (USCs). USCs express the canonical reprogramming factors c-myc and klf4, and possess high telomerase
activity. Pluripotency of urine-derived iPSC clones was confirmed by immunocytochemistry, RT-PCR and teratoma formation.
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468 X. Guan et al.using a series of small molecules in monolayer culture. Results indicate that cardiomyocytes retain the DMD patient's dystrophin
mutation. Physiological assays suggest that dystrophin-deficient cardiomyocytes possess phenotypic differences from normal
cardiomyocytes. These results demonstrate the feasibility of generating cardiomyocytes from a urine sample and that urine-derived
cardiomyocytes retain characteristic features that might be further exploited for mechanistic studies and drug discovery.
© 2013 Published by Elsevier B.V.Introduction
Mutations in the dystrophin gene cause Duchenne Muscular
Dystrophy (DMD), an X-chromosome inherited disorder af-
fecting 1:3500 male births. Considering the vast number of
dystrophin gene mutations identified and the variability in
disease phenotype in patients makes this a disease amend-
able to the benefits of personalized medicine. We propose
that induced pluripotent stem cells (iPSCs) will provide a
platform for personalized medicine in DMD.
The reprogramming of somatic cells into induced plurip-
otent stem cells (iPSCs) can provide a limitless source of
cells that can be terminally differentiated into a variety of
cell types and faithfully retain the donor's genotype as well
as phenotypic traits. These features make iPSCs a highly
desirable basic research tool for the purpose of disease
modeling, screening for therapeutic compounds and provid-
ing seed cells for autologous cell replacement therapy.
However, iPSC derivation is still an expensive and time-
consuming process (usually months) with relatively low
efficiency, in most cases less than 1% of the starting cell
number. An ideal cell source for cellular reprogramming
would be collected non-invasively, expanded easily in
culture, and reprogrammed both rapidly and efficiently.
Previously, Zhou T et al. reported that human urine could
be a novel source for iPSC derivation (Zhou et al., 2012).
Here we show that iPSCs can be generated from progenitor
cells present in human urine and be differentiated into
cardiomyocytes in monolayer culture. In our hands, USCs
exhibited faster reprogramming kinetics with higher efficiency
than human dermal fibroblasts or adult adipose derived
mesenchymal stem cells (MSCs). USC-derived iPSCs (USC-iPSCs)
expressed multiple pluripotent markers and formed teratomas
upon engraftment into immune-compromised mice, indicating
they are bona-fide pluripotent stem cells. In vitro, USC-iPSCs
derived from either healthy volunteers or from a patient
harboring a dystrophin mutation efficiently differentiated into
cardiomyocytes. Only cardiomyocytes derived from healthy
volunteers stained positive for dystrophin, whereas the cardio-
myocytes derived from a patient with a dystrophin deletion
were dystrophin negative. Physiological assays including Ca++
handling, oxidative stress, and oxygen consumption and
hypotonic stress all support the feasibility that drug-discovery
assays can be developed using urine-derived cardiomyocytes as
a biological reagent.
Materials and methods
Human subjects
Participants gave informed consent as required by the
Institutional Review Board (IRB). Healthy males (n = 3)
and one patient with Duchenne muscular dystrophy (DMD)harboring a large dystrophin deletion provided ~100 cc of a
“clean catch” urine sample.
Urine cell culture
Urine cells were isolated and expanded from urine speci-
mens as described (Zhang et al., 2008). In brief, cell pellets
were collected from whole urine samples (15–400 ml) via
centrifugation, washed with PBS, and plated as single cell
suspensions in 10 cm tissue culture dishes with a cocktail of
keratinocyte serum-free medium (KSFM; Invitrogen, Carlsbad,
CA) and DMEM/10%FBS (USC medium).
Telomerase activity (TA)
2 × 105 cells were assayed for telomerase activity using Telo
TAAGG ELISA kit (Roche Applied Sciences, Upper Bavaria,
Germany), according to the manufacturer's instructions.
HEK-293 cell lysates were used as positive controls and
heat-inactivated (85 °C for 10 min) HEK-293 cell lysates
served as the negative control. Samples were considered to
be positive for telomerase activity when the difference in
absorbance was at least twice that of the negative control.
Reprogramming vector
A polycistronic lentiviral vector encoding human Oct-3/4,
Sox2, Klf4 and c-Myc (OSKM)(Warlich et al., 2011) was
used to transduce the urine-derived cells. The fluorescent
reporter d-tomato gene was linked by an IRES element in the
construct to serve as a real-time readout of viral transgene
expression. To generate high titer viral supernatants suitable
for urine cell transduction, HEK 293T cells were transfected
with the OKSM plasmid, psPAX2 (Addgene #12260) and pMD2.G
(Addgene #12259) using the FuGENE HD Transfection Reagent
(Roche, Mannheim, Germany) according to the manufacturer's
instructions. After transfection, medium was changed daily.
Supernatants from days 2 and 3 were pooled together and
concentrated in a 100 kD Amicon Ultra Centrifugal Filter tube
(100 kD, Millipore, Billerica, MA) and frozen at −80 °C until
future use.
Cellular reprogramming
Urine-derived cells were seeded onto Matrigel (BD, San Jose,
California) coated 12 well plates at 50,000 cells/well and
allowed to attach overnight (day 0). On day two, cells were
transduced with high-titer OSKM viral supernatants in the
presence of 8 μg/ml polybrene for 3 h. Viral supernatants
were replaced with fresh USC medium and after three
days, replaced with mTeSR1 medium (StemCell Technology,
Vancouver, BC) and changed daily. As iPSC-like colonies
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pipettes under a stereo dissection microscope (Leica M205C,
Buffalo Grove, IL) and transferred to new Matrigel-coated
plates for further expansion.
Flow cytometry
Three days after viral transduction, d-tomato fluorescence
expression was assayed to assess transduction efficiency.
Briefly, cells were detached by TrypLE (Invitrogen, Grand
Island, NY) and washed three times with PBS. The fluores-
cence expression was detected using a FACSCalibur flow
cytometer (BD, San Jose, CA) and that data was analyzed
using FlowJo vX software (Tree Star, Ashland, OR).
Immunohistochemistry and alkaline phosphatase
(AP) staining
iPSCs were stained with live staining antibody Tra-1-81
(Stemgent, Cambridge, MA) and SSEA4 (BD, San Jose, CA) for
90 min at 37 °C. Cells were imaged in mTeSR1 medium after
being washed 3 times with DMEM/F12 (Chan et al., 2009).
For fluorescence immunocytochemistry of iPSCs and cardio-
myocytes, cells were passaged onto glass coverslips coated
with Matrigel. After being fixed with 4% paraformaldehyde
and permeabilized by 0.2% Triton X-100, cells were incubat-
ed with the following primary antibodies at 4 °C overnight:
Sox2 (R&D systems, Minneapolis, MN), SSEA4, Oct4, Tra-1-81
and Tra-1-60 (all from Stemgent, Cambridge, MA), cardiac
myosin heavy chain (abcam, Cambridge, MA), sarcomeric
α-actinin (thermo scientific, Rockford, IL) connexin43 (Cell
Signaling, Danvers, MA) and Cav1.3(Hell et al., 1993). For
dystrophin staining, differentiated cardiomyocytes were
plated onto glass coverslips coated with Matrigel. After
being fixed with acetone for 10 min, cardiomyocytes were
incubated with dystrophin antibody (Leica Microsystems
Inc., Buffalo Grove, IL). Fluorochrome conjugated secondary
antibodies were added the second day for 1 h at room
temperature. After counterstaining nuclei with DAPI, cover-
slips were mounted with Prolong Gold antifade reagent
(Invitrogen, Grand Island, NY). Confocal images were acquired
using a Nikon A1R confocal microscope. For alkaline phosphate
(AP) staining, iPSCs were fixed with ice cold ethanol. Color
was developed by incubating with AP staining solution (400 μl
Naphthol AS-MX Phosphate Alkaline Solution, 2.4 mg Fast Red
TR in 9.6 ml Water) for 1 h in the dark. All images were
analyzed with ImageJ (version 1.47n, National Institutes of
Health) with standard plugin.
Teratoma assay of iPSCs
All animal procedures were approved by the University's
Institution Animal Care and Use Committee. Eight to twelve
week-old female NOD/SCID mice were purchased from
Jackson Laboratory (Bar Harbor, Maine). Kidney capsule
injections were performed as described (Ritner and Bernstein,
2010). To summarize, 1 × 106 cells were injected under the
kidney capsule via a catheter connected to a Hamilton
syringe. Tumors were excised after 8–12 weeks and fixed
with 4% paraformaldehyde in PBS and embedded in paraffin.Sample blocks were sectioned at 5 μm and Hematoxylin &
Eosin (H&E) staining was performed on tumor sections.Cardiomyocyte differentiation
Urine-derived iPSCs were differentiated to cardiomyocytes
following an established protocol with modifications
(Laflamme et al., 2007). Briefly, iPSC colonies were detached
by 10 minute incubation with Versene (Life technologies,
Carlsbad, CA), triturated to a single-cell suspension and
seeded onto Matrigel-coated plastic dishes at a density of
250,000 cells/cm2 in mTeSR1 medium and cultured for 4 more
days. Differentiation was then initiated by switching the
medium to RPMI-1640 medium supplemented with 2% insulin
reduced B27 (Life Technologies) and fresh L-glutamine.RT-PCR
Total RNA was extracted from undifferentiated iPSC clones and
their corresponding cardiomyocytes using a Qiagen RNeasy kit. 1 μg
of total RNA was reverse transcribed to cDNA using an RT2 First
Strand Synthesis Kit (SA Biosciences, Valencia, CA), following the
manufacturer's instructions. cDNAs were amplified to the level of
detection using RT2 SYBR Green Master Mixes (SA Biosciences,
Valencia, CA) and individual iPSC (Cat # IPSH-001) or cardiac (Cat #
IPSH-102) markers were assayed using prefabricated arrays (SA
Biosciences, Valencia, CA). All RT-PCR data was collected on a 7300
Real Time PCR system (Applied Biosystems, Carlsbad, CA).Western blot
Dystrophin proteins were visualized by Western blot analysis
using method as previously described (Wang et al., 2012).
15 μg of cell lysates was loaded in designated lanes. DYS2
monoclonal antibody (1:50 Novocastra) was used as the
primary antibody, horse-radish peroxidase conjugated anti-
mouse antibody (1:1000, Cell Signaling) was used as the
secondary antibody. A mouse monoclonal antibody to GAPDH
(Millipore) was used as protein loading control. Western
blots were developed using ECL Plus Western Blotting
Detection System (GE Healthcare).Electrophysiological recording of
beating cardiomyocytes
Clusters of beating iPS-CM were dissociated into single cells
using Accutase (Sigma-Aldrich, St. Louis, MO) per manufac-
turer's instructions and plated on Matrigel-coated coverslips
(BD, San Jose, CA). Action potentials (AP) were recorded
using an Axopatch 200B amplifier in a current-clamp mode.
The amplifier was under the control of pClamp 10.2
software (Axon instrument, USA). APs were recorded
while iPS-CM was superfused with a solution containing
(in mM): 140 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 10
Glucose, and 1 Na-Pyruvate, adjusted to pH 7.4 with NaOH.
The patch pipettes were filled with a solution containing
(in mM): 5 NaCl, 140 KCl, 7 MgATP, and 15 HEPES, adjusted
to pH 7.2 with KOH. Pipette resistances ranged from 3 to
6 MΩ.
470 X. Guan et al.Confocal imaging of calcium flux
To monitor [Ca2+]i, iPS-CMs were loaded for 30 min with 5 μM
of the acetoxymethyl ester form of the Ca2+ indicator Fluo-4
(Fluo4-AM, Invitrogen; Kd = 345 nM). Cells were superperfused
with a Tyrode's solution. APs were evoked via field stimulation
at a frequency of 1 Hz using an Ion-Optix Myopacer (IonOptix
Corp) delivering 4-ms square voltage pulses with an amplitude
of 20 V via two platinum wires placed on each side of the
perfusion chamber base (0.5 cm separation). AP-evoked [Ca2+]
i transients were imaged using a Nikon (Eclipse TE2000-S)
Swept Field confocal system equipped with a Plan ApoA
C
E
G
B60 × 1.45 N.A. oil immersion objective, controlled with
Elements software. Fluo-4 was excited with a 488 nm
laser. Images were analyzed using Image J.
Oxygen Consumption Rate (OCR)
Cardiomyocytes differentiated from normal and DMD iPSC
were seeded at 3 × 104 cells/well into 0.1% gelatin pre-
coated SeaHorse™ plates in cardiomyocyte media (RPMI
supplemented with B27 with insulin and antibiotics). Culture
media was switched to base media (unbuffered DMEM, Sigma
D5030) supplemented with sodium pyruvate (Gibco, 1 mM)D
F
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duration of the measurement. Selective inhibitors were
injected during the measurements to achieve final concen-
trations of 4-(trifluoromethoxy) phenylhydrazone (FCCP,
1 μM), oligomycin (2.5 μM), antimycin (2.5 μM) and rote-
none (2.5 μM). Mitochondrial stress protocol starts with the
measurement of baseline oxygen consumption rate (OCR)
followed by the measurement of OCR changes in response to
the injection of oligomycin, FCCP and finally antimycin and
rotenone. The OCR values were further normalized to the
number of cells present in each well, quantified by the
Hoechst staining (HO33342; Sigma-Aldrich) as measured using
fluorescence at 355 nm excitation and 460 nm emission.
Mitochondrial Permeability Transition Pore (mPTP)
opening time
Cardiomyocytes derived from normal (n = 6) and DMD iPSCs
(n = 6) were loaded with tetramethylrhodamine ethyl ester
(TMRE), a fluorescent indicator that accumulates in the
mitochondria proportionally to the ΔWm, and exposed to
controlled and narrowly-focused laser-induced oxidative
stress until mPTP opening occurs (Pravdic et al., 2009). To
ensure equal delivery of oxidative stress among experimen-
tal groups, laser excitation settings remain consistent within
the experimental groups. Mitochondrial PTP opening was
detected by a decrease in TMRE fluorescence which indicates
loss of ΔWm. Arbitrary mPTP opening time was determined as
the time of the loss of average TMRE fluorescence intensity by
one half between initial and residual fluorescence after mPTP
opening.
Cardiomyocyte hypotonic stress assay
Hypotonic solutions were made by diluting DPBS solution to
1/2 (145 mOsm) and 1/4 (73 mOsm) osmolarity with water
(Musch et al., 1998). Normal and DMD iPS-CM were incubated
in hypotonic solutions (145 mOsm or 73 mOsm) for 30 min at
room temperature. Then osmolarity was adjusted back to
normal by adding equal volume of 435 mOsm or 507 mOsm
hypertonic solutions, for 5 min. The supernatants were
collected and analyzed for human cardiac troponin I (cTnI)
and creatine kinase-MB (CK-MB), using Meso Scale DiscoveryFigure 1 Characterization of Urine-derived stem cells (USCs). (
isolated from the urine (top) and the morphology of its derivative iPS
of USC clones assayed for expression of the reprogramming factors Oc
relative to expression of the same genes in the human embryonic st
expression is shown relative to IMR90 fibroblasts (also arbitrarily
RT-PCR for several genes highly expressed in human embryonic stem
from both healthy donor and DMD patient USC clones and compared t
USC (set at 1, y-axis). Relative values (2ΔΔCt) were normalized again
3B, DPPA4, GDF3, LEFTY1, NANOG, PODXL, POU5F1 and ZFP42.; (D)
cells and probed with antibodies highly expressed on human embryo
bar, 200 μm; (E) Flow cytometric analysis of viral transduction effici
(USC) three days after the initiation of reprogramming. The asteris
up-regulation of pluripotent surface markers SSEA4 and Tra-1-81 at
indicated by red fluorescence; (G) Overall kinetics of lentiviral-me
were kept in original medium for 3 days post viral transduction. hE
picked at indicated time.(MSD) 96 well custom human cardiac I assay (MSD, Maryland)
following the manufacturer's instructions. The plate was
imaged by SECTOR Imager 2400 (MSD, Maryland).
Statistics
Data are expressed as mean ± SD unless stated otherwise.
For the transduction efficiency study, mesenchymal cell
lines (n = 4) and USC lines (n = 7) were aggregated sepa-
rately for a Mann–Whitney U test by using GraphPad Prism 5
(GraphPad Software, Inc., La Jolla, CA). Hypotonic stress
assay was analyzed using Two-Way ANOVA. A p value less
than 0.05 was considered significant.
Results
Isolated urine cells express c-Myc and Klf4 in
addition to high telomerase activity
USCs isolated from urine samples provided by healthy
volunteers (n = 3) and a DMD patient all displayed a mesen-
chymal stem cell phenotype, including spindle-shaped mor-
phology (Fig. 1A) and expression of cell surface markers CD44,
CD73, CD90, CD105 and CD146. In addition, USCs did not
express the hematopoietic stem cell markers CD25, CD31, CD34
and CD45 (Supplemental Fig. 1). Prior to iPSC reprogramming,
four different USC clones were assayed for endogenous
expression of four classical reprogramming factors c-Myc,
Klf4, Oct4 and Sox2. Quantitative RT-PCR analysis revealed
that USCs expressed high levels of c-Myc and Klf4 relative to
human ES cells (normalized as a control), IMR90 (fetal human
lung cells) and NCCIT (mixed germ cell tumor) while expression
of Oct4 and Sox2 was negligible compared to that of hESC and
NCCIT (Fig. 1B). A high telomerase activity clone and a low
telomerase activity clone were examined using RT-PCR from
two different patients (labeled “A” and “K”). Young adult
donors (20–40 years old) produced a greater proportion of
telomerase high USC clones (75% TA high vs 25% TA low; n = 10
clones/group) than donors older than 50 years (50% TA high and
50% low; n = 10 clones/group)(Shi et al., 2012). In addition,
USCs express the kidney glomerular podocyte markers podocin
and synaptopodin (unpublished data) suggesting a mesodermal
origin of the isolated cells, consistent with their MSC-likeA) A representative phase-contrast microscopic image of cells
C colony after reprogramming (bottom); (B) Quantitative RT-PCR
t4, Sox2, Klf4 and c-Myc. Expression of Klf4 and c-Myc are shown
em (hES) cell line, H7 (marked at 1, y-axis) while Oct4 and Sox2
standardized to 1); (C) To evaluate pluripotency, quantitative
cells was compared between several iPSC clones (n = 4) derived
o hESC H9. All data were shown relative to the expression of DMD
st the housekeeping gene GAPDH and plotted for the genes DNMT
Representative iPSC colonies derived from normal human urine
nic stem cells (Tra-1-60, SSEA4, Sox2, Tra-1-81 and Oct4). Scale
ency compared between fibroblasts and cells isolated from urine
k denotes a p-value of 0.0061 (Mann–Whitney U test); (F) Early
day 7, accompanied by the down-regulation of viral transgenes,
diated reprogramming for USCs and MSCs. Both USCs and MSCs
SC medium mTeSR was added on the fourth day. Colonies were
472 X. Guan et al.morphology and marker profile. Examination of USCs isolated
from the DMD patient demonstrated a dystrophin deletion
of exon 50 (complete male DMD evaluation, test 181,
Athena Diagnostics) resulting in a frameshift mutation that
halts production of normal dystrophin protein (Supplemen-
tal Fig. 1).
Urine cells from healthy volunteers and a DMD
patient reprogram to bona fide iPSCs
The iPSC colonies derived from USCs displayed typical
pluripotent stem cell morphology (Fig. 1A). Cells appeared
tightly packed within colonies, while individual cells
displayed prominent nucleoli with an elevated nuclei/
cytoplasm ratio. Individual colonies (each representing a
unique clone) were manually picked and subcultured for
2 years without notable senescence or deterioration. Quan-
titative RT-PCR confirmed that iPSCs generated from urine
cells expressed a panel of pluripotency-related genes
comparable to those expressed by hESC H9 (Fig. 1C).
Immunofluorescent staining of iPSCs demonstrated charac-
teristic localization of several key pluripotent markers,
including Oct4, Sox2, SSEA4, Tra-1-60 and Tra-1-81 (Fig. 1D).
To verify in vivo pluripotency, four different clones of
USC-iPSCs were implanted under the kidney capsule of
NOD/SCID mice (n = 4/iPSC clone), three derived from the
urine of healthy donors and one from a DMD patient. All
iPSC clones formed multi-differentiated teratomas in at
least 3 of the 4 mice injected. Teratomas showed tissue
structures indicative of all three germ layers (ectoderm,
endoderm, and mesoderm) and comparable to teratomas
formed from the hESC H9, thus confirming that USC-iPSCs
were truly pluripotent (Supplemental Fig. 1).
Urine-derived cells reprogram to iPSCs more rapidly
than fibroblasts or MSCs
During early experiments, it was noticed that USCs formed
iPSC colonies faster than fibroblasts that were also being
reprogrammed in parallel. To test the hypothesis that USCs
reprogram faster than commonly used starting cell lines, the
efficiency and kinetics of reprogramming were compared
between USCs and mesenchymal cell lines, including a
human foreskin fibroblast line (BJ), a human fetal lung
fibroblast line (IMR90), an adipose derived MSC line
(MSC-A1), and a human skin fibroblast line (Coriell GM
04422). The efficiency of transduction was based on the
initial percentage of transduced cells which was achieved
using a multiplicity of infection (MOI) of 5. Fig. 1E shows
that 80% of the USC clones (n = 7) were successfully
transduced as indicated by the expression of a red
fluorescence reporter. In contrast, at the same MOI, only
50% of mesenchymal cell lines (n = 4) were transduced
(Fig. 1E).
To evaluate the speed of reprogramming, morphological
changes, expression of pluripotency cell surface markers
and alkaline phosphatase staining were assessed. As early
as 3 days after viral transduction, USC cell lines demon-
strated morphological changes indicative of reprogramming
(reduced cell size, increased nuclear/cytoplasmic ratio with
prominent nucleoli) while MSCs did not. By day 7, only theUSC cell lines developed individual colonies with defined
borders and expressed SSEA4 and Tra-1-81, two surface
glycoproteins that characterize the somatic to pluripotency
transition (Fig. 1F). Expression of SSEA4 and Tra-1-81 was
accompanied by silencing of viral transgenes, manifested by
the gradual decrease of d-tomato red fluorescence (Fig. 1F).
MSC lines did eventually go through similar morphological
changes and expression of pluripotency markers, but at
later time points compared to USC lines. USC-derived
iPSC colonies were mature enough to be manually picked
between days 10 and 14, whereas MSC-derived iPSC colonies
required 28 days (Fig. 1G). Together, these data indicate
that, compared to the mesenchymal lines tested, USCs are
more receptive to lentiviral transduction and reprogram
more rapidly than MSCs.
Telomerase activity is associated with improved
reprogramming efficiency
USC clones were generated by limiting dilution and assayed
for TA activity individually. A pair of USC clones derived from
three different donors (USC-A, USC-B and USC-K) was tested
(Fig. 2A). Each donor produced both telomerase high and
low clones that were subsequently tested to determine
whether telomerase activity is positively correlated with
reprogramming kinetics. 50,000 cells of each USC clone were
infected with same amount of the reprogramming lentivirus
(MOI 5). Even though iPSC colonies start to appear around
day 12, the reprogramming process was evaluated over
17 days to maximize the colony yield for all clones. The
reprogramming kinetics were comparable as all clones gave
rise to alkaline phosphatase and SSEA4 positive, transgene-
silenced colonies at day 17 (Figs. 2B and D). However, TA
exhibited a positive correlation with reprogramming effi-
ciency (Fig. 2C). Though low TA clones universally manifest-
ed a higher viral transduction rate at day 3, they generated
fewer colonies at day 17 (with calculated efficiency of
0.002% to 0.007% compared to 0.1% to 0.5% for high TA
clones) (Table 1).
Urine cells reprogram into functional cardiomyocytes
The overall goal of this work was to determine if
cardiomyocytes derived from reprogrammed urine cells
donated by a patient with a single-gene disease, can
recapitulate aspects of the disease phenotype. Therefore,
urine-derived iPSC clones were generated from a DMD
patient with a dystrophin mutation, and subsequently dif-
ferentiated into beating cardiomyocytes via in vitro mono-
layer culture. Sporadic contracting cardiomyocytes were
observed 8–20 days after initiating differentiation. The
beating loci expanded over several days and synchronized
to form a beating cell sheet (Supplemental online video 1
&2). Immunostaining confirmed that beating cells were
positive for cardiac markers sarcomeric α-actinin, cardiac
α and β myosin heavy chain (MHC), as well as membrane
localized connexin43 (Fig. 3A). Both normal and DMD
cardiomyocytes were assessed by quantitative RT-PCR and
demonstrated upregulation of a series of cardiac genes
(Fig. 3B). To investigate functionality, differentiated cardio-
myocytes were subjected to patch clamp recording. These
AC
D
B
Figure 2 Association between telomerase activity and USC reprogramming efficiency. (A) Relative telomerase activity (TA) of
various USCs clones relative to TS8, the internal positive control from the TRAP assay kit. Telomerase high and telomerase low clones
were derived from three independent donors (A, B and K); (B) alkaline phosphatase (AP) staining of reprogrammed USC clones from
(A) at day 17. Higher telomerase expression was associated with marked increase in reprogramming efficiency, indicated by the
number of AP positive colonies; (C) quantitation of photographs shown in panel B; (D) mature day 17 iPSC colonies resulting from both
high telomerase and low telomerase UC clones. Reprogrammed colonies express only SSEA4 (uniform green staining), while the
surrounding non-reprogrammed single cells still express the transgene (red fluorescence).
473Dystrophin-deficient cardiomyocytes derived from human urinecells exhibited spontaneous action potentials (AP). Based on
the amplitude, depolarization speed (dV/dt) and 50% AP
duration (APD50) differentiated cardiomyocytes were further
characterized as nodal (33%), ventricular (59%) and atrial
(9%) subtypes (Fig. 3C).Cardiomyocytes derived from the urine of a DMD
patient were dystrophin negative
Normal and dystrophin-deficient DMD cardiomyocytes were
probed with antibodies against dystrophin and cardiac-specific
Table 1 Summary of transduction and reprogramming efficiency of various USC clones.
Input cells Viral transduction
efficiency
Colony number iPS generation efficiency
(input cells * viral transduction
efficiency/colony #)
UC-A High 50000 80.4% 222 0.5522%
UC-A Low 50000 87.3% 3 0.0069%
UC-B High 50000 70.5% 192 0.5447%
UC-B low 50000 83.2% 1 0.0024%
UC-K High 50000 82.1% 5 0.0122%
UC-K low 50000 94.2% 1 0.0021%
474 X. Guan et al.markers Nkx2.5 and α-actinin. In cardiomyocytes derived from
hES H9 and normal USC iPSC, dystrophin expression was
localized to the plasma membrane. In contrast, no dystrophin
expression was detected in DMD iPSC cardiomyocytes by either
immunohistochemistry (Fig. 4A) or by immunoblot, e.g., full-
length 426 kDa dystrophin band not detected (Fig. 4B). These
findings support that DMD cardiomyocytes maintained their
dystrophin-deficient phenotype.
Physiological consequences of dystrophin
deficiency in cardiomyocytes
Several domains of cardiac function in DMD and normal
iPS-derived cardiomyocytes are demonstrated in Fig. 5,
including calcium handling, mitochondrial permeability pore
(mPTP) opening, cellular metabolism and susceptibility to
mechanical stress. Significant (p b 0.05) differences be-
tween DMD and normal cells were detected in calcium
handling: The duration of recovery (T50) of DMD calcium
transient (Fig. 5A) was prolonged compared to the normal
control (629.7 ± 20 ms vs 311.8 ± 3 ms, respectively). Mito-
chondrial permeability pore opening (Fig. 5B) occurred
earlier in DMD compared to normal controls (62 ± 14 ms
vs. 163 ± 13 s). No differences between the groups were
detected in cellular metabolism (Fig. 5C). In the hypoton-
ic stress experiment (Fig. 5D), DMD cardiomyocytes
responded with an increase of the cardiac injury marker
CK-MB and cTnI, with both markers inversely correlated
with osmolarity. In DMD cells, both cardiac injury markers
were significantly (p b 0.05) higher than normal cardio-
myocytes (145 mOsm: CK-MB = 69.6 ± 8.6 μg/ml; cTnI =
1.64 ± 0.3 μg/ml; 73 mOsm: CK-MB = 127.2 ± 11 μg/ml.
cTnI = 6.09 ± 0.4 μg/ml and 145 mOsm: CK-MB = 5.8 ±
0.1 μg/ml. cTnI = 0. 73 mOsm: CK-MB = 4.3 ± 0.02 μg/ml,
cTnI = 0, respectively).
Discussion
The isolation of a highly proliferative cell population from
human urine samples was described previously by our group
(Bharadwaj et al., 2011) as well as others (Dorrenhaus et al.,
2000; Zhou et al., 2011). Early-passage USC cultures contain
highly motile cells with the distinctive mesenchymal morphol-
ogy and an MSC-like cell surface marker profile. In this study,
USCs derived from the urine of healthy volunteers and a DMD
patient were successfully reprogrammed to bona fide iPSCs
using a conventional Yamanaka-factor, lentiviral-mediateddelivery method. More importantly, the whole reprogramming
process only took approximately three weeks from urine
sample collection to iPSC colonies, comparable to the iPSC
reprogramming kinetics reported for human hepatocytes (Liu
et al., 2010).
The endogenous expression of the reprogramming factors
c-Myc and Klf4 and high telomerase activity in USCs led to the
hypothesis that USCs may be more easily reprogrammed
compared to skin fibroblasts, the more typical starting material
for iPSC generation. To test this idea, the reprogramming
kinetics among several mesenchymal cell lines, including
fibroblasts were compared to the kinetics observed for USCs.
In all of themesenchymal lines tested, reprogramming required
at least 4 weeks, in contrast to only 2 weeks for USCs. Although
USCs intrinsically express c-Myc and Klf4, this is not likely to be
the sole reason for the observed fast kinetics. The fibroblast
IMR90 has also been shown to express comparable levels of
these two genes as USCs, but reprograms with slower kinetics.
Previous reports indicated that these two reprogramming
factors could be detected in several in vitro culture-adapted
cell types, such as human keratinocytes (Aasen et al., 2008)
and fibroblasts (Park et al., 2008a, 2008b). Another possible
contributing factor to the overall success of this approach was
that USCs were particularly receptive to lentiviral transduc-
tion. However, this was not likely to contribute to rapid iPSC
conversion. A wide range of lentiviral MOIs on these were
tested on the mesenchymal cells with little variance in
reprogramming kinetics (data not shown).
Although the addition of hTERT (increasing telomerase
activity) to the conventional four reprogramming factors
can facilitate the dedifferentiation of otherwise refractory
human cells,(Park et al., 2008a, 2008b) the high TA clones in
the present study failed to display faster reprogramming
kinetics compared to low TA clones derived from the same
donors. Moreover, various clones from different donors all
gave rise to iPSC colonies at a comparable rate, suggesting
that the fast reprogramming kinetics of USCs is independent
of telomerase activity, as well as to the donor's genetic
background. Nevertheless, high TA clones did manifest a 5-
to 192-fold increase of reprogramming efficiency, deter-
mined by the number of alkaline phosphatase-positive
colonies. Together, these observations suggest that the
effect of high telomerase activity primarily functions to
improve reprogramming efficiency, rather than accelerating
the reprogramming kinetics. The mechanism behind the fast
reprogramming kinetics of USC-iPSCs remains unclear and
large-scale transcriptome and epigenetic studies may be
necessary to elucidate the underlying mechanism.
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Figure 3 Cardiac induction from urine-derived iPSCs and characterization. (A) Immunofluorescent staining of differentiated
cardiomyocytes. Both normal and DMD cardiomyocytes stained positive for cardiac sarcomeric α-actinin, cardiac Myosin Heavy Chain
(MHC), and membrane localized connexin 43; (B) quantitative RT-PCR of cardiomyocytes differentiated from both DMD and normal
USC-iPSCs. Data shown in relative to the expression of parental iPSCs. Relative values were normalized against the housekeeping gene
GAPDH and plotted for the genes ACTN2, CKM, DES, GATA4, HAND2, KCNQ1, MB, MYH7, MYL2, MYL3, MYL7, NKX2-5, NPPA, PLN, RYR2,
SLC8A1, TNNI3, and TNNT2. (C) Action Potential (AP) recordings of normal iPS derived cardiomyocytes. Representative traces of the
spontaneous firing of ventricular-like and nodal-like cells and the evoked AP of a quiescent atrial-like cell. Percentage distribution of
ventricular, atrial, and nodal phenotypes (n = 30). Bar plots summarize the characteristics of the AP for the three phenotypes
(mean ± SEM).
475Dystrophin-deficient cardiomyocytes derived from human urineiPSC technology permits the preservation of the individ-
ual's unique genotype in reprogrammed pluripotent stem
cells, which can be further differentiated into various
specialized somatic cells. Our findings are in keeping witha recent report (Dick et al., 2013) where iPSCs derived from
DMD patients harboring various dystrophin mutations main-
tained these unique mutations following cardiomyocyte
differentiation. Due to the cardiomyopathy that develops
AB
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Figure 5 Potential physiological readouts for high throughput screening in iPS derived cardiomyocytes. (A) Single cell tracing of
evoked Ca2+ transients from a normal and a dystrophin-deficient iPS-derived cardiomyocyte (Normal and DMD iPS-CM) loaded with a
Ca2+ indicator. Individual cells were paced at 1 Hz and a confocal microscope recorded the resulting Ca2+ signal. Typical tracing of
normal and DMD iPSC-CM Ca2+ transients are displayed on the left. Bar plots summarize the duration of the recovery of the calcium
transient (T50) (Normal iPSC-CM, n = 3; DMD iPSC-CM, n = 3). (B) Individual cardiomyocytes derived from normal and DMD iPS were
loaded with an inner mitochondria membrane potential (ΔΨm) dye Tetramethylrhodamine ethyl ester (TMRE). Oxidative stress,
induced by controled laser exposure, causes mitochondria permeability transition pore (mPTP) opening which leads to a decrease in
TMRE fluorescence, indicating the loss of ΔΨm. A representative readout of the TMRE fluorescence decay is shown between a normal
and DMD iPS-CM (open and closed circles, respectively). The mean calculated mPTP opening time, determined as the half decay time
of the average initial TMRE fluorescence intensity, is presented by bar graph for (n = 6) experiments. (C) Oxygen consumption rate
(OCR) of normal and DMD iPS-CMs (n = 6 plates of cells) measured using the Seahorse™ XF96 Extracellular Flux analyzer. Selective
inhibitors were injected during the measurements as indicated. OCR was measured at baseline and following injection of various
inhibitors, and values were normalized to the number of cells present in each well. (D) Cardiac damage following hypotonic stress.
Normal and DMD iPS-CM were incubated in hypotonic solutions as indicated for 30 min. The supernatants were analyzed for human
cardiac troponin I (cTnI) and creatine kinase-MB (CK-MB). DMD cells released show markedly elevated levels of both injury markers
whereas only negligible amounts were detected from normal CMs. (E) Physiological assays described above (A–D) could be adapted to
a high throughput format to serve as initial readouts or as confirmation of “hits” for drug discovery. Legend: Bar plots: mean ± SD.
***p b 0.001; **0.001 b p b 0.01; *0.01 b p b 0.05. Oligo = oligomycine; FCCP = 4-(trifluoromethoxy) phenylhydrazone; Anti/Rot =
antimycin and rotenone; Osm = osmolar.
477Dystrophin-deficient cardiomyocytes derived from human urinein patients with DMD, we chose to differentiate USC-iPSCs
into cardiomyocytes. Exon analysis of urine cell genomic DNA
confirmed the exon 50 deletion in the dystrophin gene. SinceFigure 4 Immunohistochemical staining of cardiomyocytes deriv
(A) Cardiomyocytes derived from normal and DMD USC-iPSCs were p
specific protein Nkx2-5 or sarcomeric α-actinin. Dystrophin stainin
cardiomyocytes derived from the DMD patient; (B) Western blot f
iPS-derived cardiomyocytes (lane 2) and human heart tissue (lane
Molecular weight markers (in kDa) are shown on the left.this is an out-of-frame mutation, the cells should not be able
to translate the dystrophin protein. Immunofluorescence
for dystrophin revealed that DMD cardiomyocytes did noted from the urine of a DMD patient and a normal volunteer.
robed with antibodies against dystrophin, together with cardiac
g is only demonstrated in normal cardiomyocytes, but not in
or full length dystrophin detected in the lysates from normal
3) but absent in the lysate from DMD cardiomyocytes (lane 1).
478 X. Guan et al.express the protein thus maintaining the disease-causing
condition in the terminally differentiated cells suitable for
study.
The majority of DMD patients develop cardiac abnormal-
ities, with congestive heart failure (CHF) and sudden cardiac
death directly account for 10–20% of the mortality in these
young patients. Cardiac manifestations include rhythmic
disturbance, heart structural alteration and hemodynamic
abnormalities. Although the pathogenesis of dystrophin defi-
cient cardiomyopathy is still not fully understood, evidence
supports that disruption of the dystroglycan complex predis-
poses dystrophin-deficient cardiomyocytes to load-induced
sarcolemma damage. The subsequent cascade of abnormal
signaling events eventually leads to cell death, triggering
inflammation further exacerbating tissue pathology. Several
pathways have been suggested in the disease process, but none
of them have been confirmed in human DMD cardiomyocytes.
The lack of information can largely be explained by the risk
associated with a patient heart biopsy, as well as the fact
that cardiac cells derived from patients cannot be well
maintained and expanded in culture. iPSCs from DMD
patients can be a source of cardiac tissue in which to base
experiments.
In the present study, we explored four cellular physio-
logical domains using established assays (Fig. 5) to assess
potential phenotype abnormalities associated with dystro-
phin deficiency. While our preliminary data must be inter-
preted cautiously until additional biological replicates
with isogenic controls are completed, the strong signal
obtained from the “stress assay” (Fig. 5D) supports the
idea that dystrophin deficiency renders the cardiomyocyte
abnormally vulnerable to mechanical stress. This idea is
supported by a line of evidence in dystrophin-deficient
skeletal muscle(Allen et al., 2010; Childers et al., 2002;
Childers et al., 2001; Childers et al., 2005; Deconinck and
Dan, 2007; Grounds, 2008) and to a lesser extent in cardiac
muscle (De Pooter et al., 2012; Phillips and Quinlivan, 2008).
While the concept of increased susceptibility to stress might
be considered a foregone conclusion, to our knowledge,
stress assays conducted in iPS-derived DMD cardiomyocytes
have not yet been reported. Moreover, questions remain
about the underlying pathophysiology of cardiomyopathy in
DMD patients (Judge et al., 2011). Evidence in mice (Crisp et
al., 2011) suggests that cardiac dysfunction results from the
heart developing in the face of progressively fatal respira-
tory muscle failure. In other words, heart failure in DMD
patients develops secondary to respiratory failure and not as
a direct consequence of dystrophin deficiency. However,
this concept has been debated in the literature (Wasala et
al., 2013) and until now, this hypothesis has never been
directly tested. Invention of iPS technology allows us to
conduct physiological tests in patient-derived heart cells
developed completely outside of the body. Our initial
readouts from iPS-derived cardiomyocytes support the idea
that dystrophin deficiency directly results in an increased
susceptibility to mechanical damage and liberation of
cardiac-specific injury markers. These markers, CK-MB and
cTnI are widely used by clinicians for the detection of
myocardial damage in the face of a suspected heart attack
(Adams et al., 1993; Hoogerwaard et al., 2001). DMD
patients, in particular, are abnormally vulnerable to cardiac
injury as demonstrated by elevated cTnI and CK-MB levels(Ramaciotti et al., 2003; Townsend et al., 2010). Further-
more, several observations have been made that these
cardiac markers are powerful predictors of cardiac events in
patients with heart failure and in the general population
(Arenja et al., 2012). Cardiac injury markers are also used
to assess the efficacy of cardioprotective treatments in
general (Mangiacapra et al., 2013). Thus, the iPS-derived
cardiomyocytes generated from patient urine samples
provide a novel biological resource for personalized medi-
cine. This new resource might further be exploited using
one or more of the assays reported here to discover
new compounds or test existing drugs that can protect
dystrophin-deficient heart cells from stress-induced dam-
age. Compounds identified in this way have a higher
likelihood of working in the patient since they were tested
in the patient's own cells.
Conclusions
We have shown the feasibility of rapid iPSC generation from
human urine samples that can subsequently differentiate
into beating cardiomyocytes. The cells found in human urine
manifest unique features for iPSC generation, including ease
of collection, intrinsic expression of reprogramming factors
c-Myc and Klf4, and high telomerase activity. Our findings
also support the idea that cardiomyocytes derived from the
urine of a dystrophin-mutant DMD patient maintain the
dystrophin-deficient phenotype and display unique features
which might be further exploited in mechanistic studies or in
drug discovery assays.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.12.004.
Acknowledgments
This work was supported by grants from the National Institutes of
Health (K18HL102884-01) and the Muscular Dystrophy Association
(MDA201127). MWL is supported by NIH grants (K08 AR059750 & L40
AR057721). JM is supported by a fellowship from the American
Heart Association. HRB is supported by NIH grants (R01GM097372,
R01GM083867 and 1P01GM081619). We acknowledge the Children's
Research Institute Histology Core Facility at the Medical College of
Wisconsin for the sectioning and staining of tumor specimens and Dr.
Didier Trono for providing the lentiviral packaging vectors.
References
Aasen, T., Raya, A., Barrero, M.J., Garreta, E., Consiglio, A., Gonzalez,
F., Izpisua Belmonte, J.C., 2008. Efficient and rapid generation
of induced pluripotent stem cells from human keratinocytes.
Nat. Biotechnol. 26 (11), 1276–1284. http://dx.doi.org/10.1038/
nbt.1503 (doi: nbt.1503 [pii]).
Adams 3rd, J.E., Bodor, G.S., Davila-Roman, V.G., Delmez, J.A.,
Apple, F.S., Ladenson, J.H., Jaffe, A.S., 1993. Cardiac troponin
I. A marker with high specificity for cardiac injury. [Comparative
Study Research Support, Non-U.S. Gov't Research Support,
U.S. Gov't, P.H.S.]. Circulation 88 (1), 101–106.
Allen, D.G., Zhang, B.T., Whitehead, N.P., 2010. Stretch-induced
membrane damage in muscle: comparison of wild-type and
mdx mice. [Research Support, Non-U.S. Gov't Review]. Adv. Exp.
Med. Biol. 682, 297–313. http://dx.doi.org/10.1007/978-1-
4419-6366-6_17.
479Dystrophin-deficient cardiomyocytes derived from human urineArenja, N., Reichlin, T., Drexler, B., Oshima, S., Denhaerynck, K.,
Haaf, P., Mueller, C., 2012. Sensitive cardiac troponin in
the diagnosis and risk stratification of acute heart failure.
[Comparative Study]. J. Intern. Med. 271 (6), 598–607.
http://dx.doi.org/10.1111/j.1365-2796.2011.02469.x.
Bharadwaj, S., Liu, G., Shi, Y., Markert, C., Andersson, K.E., Atala,
A., Zhang, Y., 2011. Characterization of urine-derived stem cells
obtained from upper urinary tract for use in cell-based
urological tissue engineering. Tissue Eng. A 17 (15–16),
2123–2132. http://dx.doi.org/10.1089/ten.TEA.2010.0637.
Chan, E.M., Ratanasirintrawoot, S., Park, I.H., Manos, P.D., Loh, Y.H.,
Huo, H., Schlaeger, T.M., 2009. Live cell imaging distinguishes
bona fide human iPS cells from partially reprogrammed cells.
Nat. Biotechnol. 27 (11), 1033–1037. http://dx.doi.org/10.1038/
nbt.1580 (nbt.1580 [pii]).
Childers, M.K., Okamura, C.S., Bogan, D.J., Bogan, J.R., Sullivan,
M.J., Kornegay, J.N., 2001. Myofiber injury and regeneration in a
canine homologue of Duchenne muscular dystrophy. Am. J. Phys.
Med. Rehabil. 80 (3), 175–181.
Childers, M.K., Okamura, C.S., Bogan, D.J., Bogan, J.R., Petroski,
G.F., McDonald, K., Kornegay, J.N., 2002. Eccentric contraction
injury in dystrophic canine muscle. Arch. Phys. Med. Rehabil. 83
(11), 1572–1578 (S000399930200254X [pii]).
Childers, M.K., Staley, J.T., Kornegay, J.N., McDonald, K.S.,
2005. Skinned single fibers from normal and dystrophin-
deficient dogs incur comparable stretch-induced force defi-
cits. Muscle Nerve 31 (6), 768–771. http://dx.doi.org/10.1002/
mus.20298.
Crisp, A., Yin, H., Goyenvalle, A., Betts, C., Moulton, H.M., Seow,
Y., Wood, M.J., 2011. Diaphragm rescue alone prevents heart
dysfunction in dystrophic mice. [Research Support, Non-U.S.
Gov't]. Hum. Mol. Genet. 20 (3), 413–421. http://dx.doi.org/
10.1093/hmg/ddq477.
De Pooter, J., Vandeweghe, J., Vonck, A., Loth, P., Geraedts, J.,
2012. Elevated troponin T levels in a female carrier of Duchenne
muscular dystrophy with normal coronary angiogram: a case
report and review of the literature. [Case Reports Review]. Acta
Cardiol. 67 (2), 253–256.
Deconinck, N., Dan, B., 2007. Pathophysiology of duchenne muscular
dystrophy: current hypotheses. [Review]. Pediatr. Neurol. 36 (1),
1–7. http://dx.doi.org/10.1016/j.pediatrneurol.2006.09.016.
Dick, E., Kalra, S., Anderson, D., George, V., Ritso, M., Laval, S.H.,
Denning, C., 2013. Exon skipping and gene transfer restore
dystrophin expression in human induced pluripotent stem cells-
cardiomyocytes harboring DMD mutations. Stem Cells Dev.
http://dx.doi.org/10.1089/scd.2013.0135.
Dorrenhaus, A., Muller, J.I., Golka, K., Jedrusik, P., Schulze, H.,
Follmann, W., 2000. Cultures of exfoliated epithelial cells from
different locations of the human urinary tract and the renal
tubular system. Arch. Toxicol. 74 (10), 618–626.
Grounds, M.D., 2008. Two-tiered hypotheses for Duchenne muscular
dystrophy. [Review]. Cell. Mol. Life Sci. 65 (11), 1621–1625.
http://dx.doi.org/10.1007/s00018-008-7574-8.
Hell, J.W., Westenbroek, R.E., Warner, C., Ahlijanian, M.K.,
Prystay, W., Gilbert, M.M., Catterall, W.A., 1993. Identification
and differential subcellular localization of the neuronal class C
and class D L-type calcium channel alpha 1 subunits. [Research
Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
J. Cell Biol. 123 (4), 949–962.
Hoogerwaard, E.M., Schouten, Y., van der Kooi, A.J., Gorgels, J.P.,
de Visser, M., Sanders, G.T., 2001. Troponin T and troponin I in
carriers of Duchenne and Becker muscular dystrophy with cardiac
involvement. Clin. Chem. 47 (5), 962–963.
Judge, D.P., Kass, D.A., Thompson, W.R., Wagner, K.R., 2011.
Pathophysiology and therapy of cardiac dysfunction in Duchenne
muscular dystrophy. [Research Support, Non-U.S. Gov't Review].
Am. J. Cardiovasc. Drugs 11 (5), 287–294. http://dx.doi.org/
10.2165/11594070-000000000-00000.Laflamme, M.A., Chen, K.Y., Naumova, A.V., Muskheli, V., Fugate,
J.A., Dupras, S.K., Murry, C.E., 2007. Cardiomyocytes derived
from human embryonic stem cells in pro-survival factors enhance
function of infarcted rat hearts. Nat. Biotechnol. 25 (9),
1015–1024. http://dx.doi.org/10.1038/nbt1327 (nbt1327 [pii]
[doi].).
Liu, H., Ye, Z., Kim, Y., Sharkis, S., Jang, Y.Y., 2010. Generation
of endoderm-derived human induced pluripotent stem cells from
primary hepatocytes. Hepatology 51 (5), 1810–1819. http://
dx.doi.org/10.1002/hep.23626.
Mangiacapra, F., Peace, A.J., Di Serafino, L., Pyxaras, S.A.,
Bartunek, J., Wyffels, E., Barbato, E., 2013. Intracoronary
enalaprilat to reduce microvascular damage during percuta-
neous coronary intervention (ProMicro) study. [Randomized
controlled trial]. J. Am. Coll. Cardiol. 61 (6), 615–621.
http://dx.doi.org/10.1016/j.jacc.2012.11.025.
Musch, M.W., Davis-Amaral, E.M., Vandenburgh, H.H., Goldstein,
L., 1998. Hypotonicity stimulates translocation of ICln in
neonatal rat cardiac myocytes. Pflugers Arch. 436 (3),
415–422.
Park, I.-H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A.,
Daley, G.Q., 2008a. Reprogramming of human somatic cells to
pluripotency with defined factors. [http://dx.doi.org/10.1038/
nature06534] Nature 451 (7175), 141–146 (http://www.nature.
com/nature/journal/v451/n7175/suppinfo/nature06534_S1.html).
Park, I.H., Lerou, P.H., Zhao, R., Huo, H., Daley, G.Q., 2008b.
Generation of human-induced pluripotent stem cells. Nat. Protoc.
3 (7), 1180–1186. http://dx.doi.org/10.1038/nprot.2008.92
(nprot.2008.92 [pii][doi]).
Phillips, M.F., Quinlivan, R., 2008. Calcium antagonists for Duchenne
muscular dystrophy. [Review]. Cochrane Database Syst. Rev. 4.
http://dx.doi.org/10.1002/14651858.CD004571.pub2 (CD004571.).
Pravdic, D., Sedlic, F., Mio, Y., Vladic, N., Bienengraeber, M.,
Bosnjak, Z.J., 2009. Anesthetic-induced preconditioning delays
opening of mitochondrial permeability transition pore via
protein Kinase C-epsilon-mediated pathway. [In Vitro Research
Support, N.I.H., Extramural]. Anesthesiology 111 (2), 267–274.
http://dx.doi.org/10.1097/ALN.0b013e3181a91957.
Ramaciotti, C., Iannaccone, S.T., Scott, W.A., 2003. Myo-
cardial cell damage in Duchenne muscular dystrophy. [Case
Reports Research Support, U.S. Gov't, P.H.S.]. Pediatr.
Cardiol. 24 (5), 503–506. http://dx.doi.org/10.1007/s00246-002-
0408-9.
Ritner, C., Bernstein, H.S., 2010. Fate mapping of human
embryonic stem cells by teratoma formation. J. Vis. Exp. 42,
e2036. http://dx.doi.org/10.3791/2036.
Shi, Y., Liu, G., Shantaram, B., Atala, A., Zhang, Y., 2012. Urine
derived stem cells with high telomerase activity for cell based
therapy in urology. [Abstract]. J. Urol. 187 (4, Supplement).
http://dx.doi.org/10.1016/j.juro.2012.02.821 (1.).
Townsend, D., Turner, I., Yasuda, S., Martindale, J., Davis, J.,
Shillingford, M., Metzger, J.M., 2010. Chronic administration
of membrane sealant prevents severe cardiac injury and
ventricular dilatation in dystrophic dogs. J. Clin. Invest. 120
(4), 1140–1150. http://dx.doi.org/10.1172/JCI41329 (41329
[pii]).
Wang, Z., Storb, R., Halbert, C.L., Banks, G.B., Butts, T.M., Finn,
E.E., Tapscott, S.J., 2012. Successful regional delivery and long-
term expression of a dystrophin gene in canine muscular
dystrophy: a preclinical model for human therapies. [Research
Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
Mol. Ther. 20 (8), 1501–1507. http://dx.doi.org/10.1038/
mt.2012.111.
Warlich, E., Kuehle, J., Cantz, T., Brugman, M.H., Maetzig, T.,
Galla, M., Schambach, A., 2011. Lentiviral vector design and
imaging approaches to visualize the early stages of cellular
reprogramming. Mol. Ther. 19 (4), 782–789. http://dx.doi.org/
10.1038/mt.2010.314 (mt2010314 [pii]).
480 X. Guan et al.Wasala, N.B., Bostick, B., Yue, Y., Duan, D., 2013. Exclusive skeletal
muscle correction does not modulate dystrophic heart disease in
the aged mdx model of Duchenne cardiomyopathy. Hum. Mol.
Genet. http://dx.doi.org/10.1093/hmg/ddt112.
Zhang, Y., McNeill, E., Tian, H., Soker, S., Andersson, K.E., Yoo,
J.J., Atala, A., 2008. Urine derived cells are a potential source
for urological tissue reconstruction. J. Urol. 180 (5), 2226–2233.
http://dx.doi.org/10.1016/j.juro.2008.07.023 (S0022-5347(08)
01820-X [pii]).Zhou, T., Benda, C., Duzinger, S., Huang, Y., Li, X., Li, Y.,
Esteban, M.A., 2011. Generation of induced pluripotent stem
cells from urine. J. Am. Soc. Nephrol. 22 (7), 1221–1228.
http://dx.doi.org/10.1681/ASN.2011010106 (ASN.2011010106
[pii]).
Zhou, T., Benda, C., Dunzinger, S., Huang, Y., Ho, J.C., Yang, J.,
Esteban, M.A., 2012. Generation of human induced pluripotent
stem cells from urine samples. Nat. Protoc. 7 (12), 2080–2089.
http://dx.doi.org/10.1038/nprot.2012.115.
